Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A non-interventional, multi-center, prospective study of cabotegravir and rilpivirine in people living with HIV in a real-world setting

Next Previous
Trial Profile

A non-interventional, multi-center, prospective study of cabotegravir and rilpivirine in people living with HIV in a real-world setting

Status: Completed
Phase of Trial: Phase IV

Latest Information Update: 18 Jul 2024

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Cabotegravir+rilpivirine (Primary) ; Cabotegravir+rilpivirine
  • Indications HIV-1 infections
  • Focus Adverse reactions
  • Acronyms German CARLOS cohort

Most Recent Events

  • 15 Jul 2024 According to a ViiV Healthcare media release, results form this study will be presented at the 25th International AIDS Conference in Munich, Germany (22 -26 July).
  • 26 Oct 2022 Interim Results(n=236) assessing Six-month outcomes of effectiveness, adherence to injections and patient-reported outcomes of cabotegravir and rilpivirine in aptients living with HIV presented at the 16th International Congress on Drug Therapy and HIV Infection
  • 26 Oct 2022 Interim results reporting quantitative on data concerns, barriers and facilitators of implementation of LA therapy from a health-care provider perspective presented at the 16th International Congress on Drug Therapy and HIV Infection

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top